The US health care system has long struggled to provide access to essential care.
But, now, with the opioid epidemic threatening to spiral out of control, the US has a problem that is unprecedented in its magnitude.
The problem is that the US health system has been unable to address it.
The opioid crisis, which has hit the US hardest, has led to a surge in drug-resistant infections and a severe shortage of doctors and other health workers, exacerbating a health crisis already being exacerbated by a massive increase in the use of prescription opioids.
The US has the third highest number of hospitalizations per capita in the world, according to a report by the World Health Organization (WHO).
And the cost of treating such a huge increase in drug use is high, especially for the uninsured.
It’s estimated that $300 billion worth of drugs have been prescribed to the US in 2017 alone.
It’s not just the US that is grappling with this problem.
Canada is also in the midst of a major opioid crisis.
In the past three years, more than 5,000 Canadians have died of drug overdoses.
Canada has taken a series of drastic steps to address the opioid crisis in recent months.
In September, the federal government announced it was imposing strict new regulations for the manufacture, distribution and possession of opioid drugs.
This came after a national survey showed nearly a quarter of Canadians believe the government has not done enough to curb the opioid addiction epidemic.
And in April, Canada introduced legislation allowing doctors to prescribe and dispense opioid painkillers without a prescription.
This is a long overdue step, but it’s also one that is being resisted by the pharmaceutical industry.
As it stands, patients can still buy a prescription for a generic opioid without the need for a doctor’s prescription.
And many pharmacies will still offer these drugs to patients with no prescription.
However, there is a growing backlash from the pharmaceutical companies who argue that this change would create a black market in prescription opioids, and it would mean they would be forced to increase prices and restrict access to care.
The Canadian pharmaceutical industry, in particular, has taken the side of the pharmaceutical lobby in its push to prevent the government from taking any measures to restrict access.
In fact, the pharmaceuticals lobby in the US was the first to make a big push against the federal changes, and the US pharmaceutical companies have even joined Canadian governments in calling for a nationwide ban on generic opioids.
This has been a powerful strategy because it has helped drive up the price of generic opioids in the United States, which is hurting the US economy in a number of ways.
But the push by the drug companies is also being countered by the healthcare providers who are increasingly feeling the strain of the opioid problem.
And they’re not alone.
The health system in Canada is in a desperate state, and many health care workers are struggling with the consequences of an opioid crisis that has been worsened by a shortage of health care staff.
The opioid crisis has hit Canada hardest, and a growing number of Canadians are experiencing health issues like opioid addiction and hospitalizations.
The Canadian Health Service (CHS) has recorded more than 2,200 hospitalizations for overdoses in 2017.
In fact, nearly 30 per cent of CHS employees are experiencing a substance abuse disorder.
In recent weeks, the CHS has been experiencing a surge of new opioid prescriptions for the first time since the opioid pandemic began.
And the CHL is seeing a significant spike in new opioid-related infections.
In an attempt to contain the problem, the Canadian government introduced a series